Back to list

Delfi Diagnostics

Developer of a blood test system designed for the early detection of cancer.
Biotechnology 📍 Palo Alto, CA Founded 2019
Current Valuation
$725M
as of 2024-Q2
PRIVATE
Developer of a blood test system designed for the early detection of cancer.

Company Profile

Founded
2019
HQ
Palo Alto, CA
Employees
175
Total Raised
$431.57M
Last Round
Series B — $100M (Jun 2024)
IPO Status
private

Fundraising Status

Series B · $100M · 2y 2mo ago
privateTotal raised $431.57M

Secondary Market

Implied price / share
$1.02
Last round price / share
$4.84
vs last round
-78.9%
Last round price vs secondary price
Last round vs current secondary price per share$4.84Last round$1.02Current
Secondary price return by period
Secondary market period returns3-month0.0%6-month+15.9%1-year-2.9%All-time-75.3%
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Series B$100MJun 2024$725M
MedicalHealth CareBiotechnologyHealth Diagnostics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q2. Refreshed quarterly.